| XENCOR INC. DL-,01 |
| USA |
| Gesundheit |
| US98401F1057 / A1W96L |
| XE9 (Frankfurt) / XNCR (NASDAQ) |
| FRA:XE9, ETR:XE9, XE9:GR, NASDAQ:XNCR |
| - |
| https://xencor.com/ |
|
Xencor Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of engineered monoclonal antibodies and antibody therapeutics. Powered by its proprietary XmAb p..
>Volltext.. |
| 778.01 Mio. EUR |
| 469.05 Mio. EUR |
| 108.31 Mio. EUR |
| -144.02 Mio. EUR |
| -79.28 Mio. EUR |
| -1.07 EUR |
| 161.93 Mio. EUR |
| 46.64 Mio. EUR |
| -116.53 Mio. EUR |
| 5.71 |
| 0.17% |
| 65.17% |
| - |
| - |
| - |
| XENCOR |
| 05.03.26 |
|